CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.02B, above the global median of $1.15B
- FinancialsAltman Z-Score 1.6: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.02BUSDvs all stocks (USD)
Revenue (TTM)
143.05MUSDvs all stocks (USD)
Profit Margin
-102.06%vs Biotechnology peers
Beta
1.53xvs all stocks
52-Week Change
146.81%vs all stocks
Market Capitalization
2.02BUSDvs all stocks (USD)
Enterprise Value
1.65BUSDvs all stocks (USD)
Forward P/E
-96.75xvs Biotechnology peers
Price to Sales (TTM)
14.13xvs Biotechnology peers
Price to Book (MRQ)
6.32xvs Biotechnology peers
Enterprise to Revenue
11.52xvs Biotechnology peers
Enterprise to EBITDA
-11.11xvs Biotechnology peers
Gross Margin
92.80%vs Biotechnology peers
Profit Margin
-102.06%vs Biotechnology peers
Operating Margin
4.66%vs Biotechnology peers
Return on Assets (TTM)
-17.02%vs Biotechnology peers
Return on Equity (TTM)
-39.51%vs Biotechnology peers
Revenue (TTM)
143.05MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4160USDUpdated Jul 19, 2026Quarterly Revenue Growth
2598.70%vs Biotechnology peers
Gross Profit (TTM)
129.85MUSDvs all stocks (USD)
EBITDA (TTM)
-148.21MUSDvs all stocks (USD)
Net Income (TTM)
-145.99MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
2598.70%vs Biotechnology peers
Operating Cash Flow (TTM)
-125.73MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-100.04MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
62.90MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
9.30MUSDFY2025 · Dec 31, 2025Gross Profit
53.60MUSDFY2025 · Dec 31, 2025Operating Income
-213.06MUSDvs all stocks (USD)
Pre-tax Income
-204.63MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-204.63MUSDFY2025 · Dec 31, 2025EBIT
-190.94MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-188.37MUSDFY2025 · Dec 31, 2025Research & Development
115.11MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
151.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
21.43MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
13.68MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-204.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-175.98MUSDFY2025 · Dec 31, 2025Free Cash Flow
-176.34MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.74M of depreciation against 354K of capital expenditure, and its own free-cash-flow line reads -181.78M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
164.09MUSDFY2025 · Dec 31, 2025Income Tax Paid
197.00KUSDFY2025 · Dec 31, 2025Interest Paid
2.88MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-204.63MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.74MUSDFY2025 · Dec 31, 2025Stock-based Compensation
35.89MUSDFY2025 · Dec 31, 2025Other Non-cash Items
11.07MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.07MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.13MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.13MUSDFY2025 · Dec 31, 2025Capital Expenditures
-354.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-8.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-354.42MUSDFY2025 · Dec 31, 2025Sale of Investments
462.29MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
107.52MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-11.90MUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
48.20MUSDFY2025 · Dec 31, 2025Other Financing Charges
142.91MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
179.22MUSDFY2025 · Dec 31, 2025Shares Outstanding
347.69MSharesUpdated Jul 19, 2026Float Shares
254.66MSharesUpdated Jul 19, 2026Shares Short
54.36MSharesUpdated Jul 19, 2026Short Ratio
6.59daysvs all stocks
Short % of Shares Outstanding
25.85%vs all stocks
% Held by Insiders
18.59%vs all stocks
% Held by Institutions
64.86%vs all stocks
Total Cash (MRQ)
533.73MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.53USDUpdated Jul 19, 2026Total Debt (MRQ)
216.98MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6790xvs Biotechnology peers
Current Ratio (MRQ)
7.44xvs Biotechnology peers
Book Value per Share (MRQ)
0.9190USDUpdated Jul 19, 2026Total Assets
594.82MUSDvs all stocks (USD)
Total Current Assets
571.52MUSDFY2025 · Dec 31, 2025Total Liabilities
289.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
23.30MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
206.88MUSDFY2025 · Dec 31, 2025Total Current Liabilities
82.23MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
164.09MUSDFY2025 · Dec 31, 2025Other Short-term Investments
365.13MUSDFY2025 · Dec 31, 2025Accounts Receivable
16.08MUSDFY2025 · Dec 31, 2025Inventory
11.41MUSDFY2025 · Dec 31, 2025Accounts Payable
9.48MUSDFY2025 · Dec 31, 2025Short-term Debt
7.60MUSDFY2025 · Dec 31, 2025Deferred Revenue
7.51MUSDFY2025 · Dec 31, 2025Other Current Liabilities
12.45MUSDFY2025 · Dec 31, 2025Long-term Debt
49.75MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
145.82MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.42BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.12BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
305.72MUSDvs all stocks (USD)
52-Week Low
2.18USDUpdated Jul 19, 202652-Week High
9.75USDUpdated Jul 19, 202652-Week Change
146.81%vs all stocks
Beta
1.53xvs all stocks
50-Day MA
5.17USDUpdated Jul 19, 2026200-Day MA
5.55USDUpdated Jul 19, 2026Avg 10-Day Volume
5.93MSharesUpdated Jul 19, 2026Avg 30-Day Volume
7.79MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.4300USDUpdated Jul 19, 2026Other Income / Expense
689.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.93Profit Margin: -1.02
Financial Health
Altman Z-Score 1.6: grey zoneSignificant
Altman Z-Score: 1.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.02B, above the global median of $1.15BNotable
Market cap (USD): 2,019,571,431Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Syndax Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Caplin Point Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rapport Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule